Literature DB >> 11218052

Topiramate in the catastrophic epilepsies of childhood.

T A Glauser1.   

Abstract

Several epileptic syndromes that occur during childhood are characterized by severe treatment-resistant seizures, progressive loss of higher intellectual functions, and characteristic electroencephalographic abnormalities. These catastrophic epileptic syndromes include epileptic encephalopathy with diffuse slow spike waves (Lennox-Gastaut syndrome), West syndrome, progressive myoclonic epilepsies, and electrical status epilepticus during sleep. This article summarizes each syndrome and reviews the most recent information concerning the effectiveness of topiramate with respect to each condition. Suggestions are offered to help clinicians maximize topiramate's efficacy and tolerability in patients suffering with these syndromes. Overall, topiramate is a valuable antiepileptic medication in the treatment of catastrophic pediatric epileptic syndromes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11218052     DOI: 10.1177/0883073800015001S04

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  5 in total

1.  Topiramate as a new antiepileptic drug in epileptic children in Iran.

Authors:  R Fallah
Journal:  Indian J Pediatr       Date:  2006-12       Impact factor: 1.967

2.  A new generation of anticonvulsants for the treatment of epilepsy in children.

Authors:  O Carter Snead; Elizabeth J Donner
Journal:  Paediatr Child Health       Date:  2007-11       Impact factor: 2.253

3.  Early-Life Epilepsies and the Emerging Role of Genetic Testing.

Authors:  Anne T Berg; Jason Coryell; Russell P Saneto; Zachary M Grinspan; John J Alexander; Mariana Kekis; Joseph E Sullivan; Elaine C Wirrell; Renée A Shellhaas; John R Mytinger; William D Gaillard; Eric H Kossoff; Ignacio Valencia; Kelly G Knupp; Courtney Wusthoff; Cynthia Keator; William B Dobyns; Nicole Ryan; Tobias Loddenkemper; Catherine J Chu; Edward J Novotny; Sookyong Koh
Journal:  JAMA Pediatr       Date:  2017-09-01       Impact factor: 16.193

Review 4.  Treatment of epileptic encephalopathies.

Authors:  Amy McTague; J Helen Cross
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

Review 5.  New generation anticonvulsants for the treatment of epilepsy in children.

Authors:  Elizabeth J Donner; O Carter Snead
Journal:  NeuroRx       Date:  2006-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.